Endocrinology Research Analysis
Endocrinology in 2025-Q4 coalesced around actionable cardio-renal-metabolic therapeutics and mechanistic blueprints for disease modification. First-in-class clinical advances included an aldosterone synthase inhibitor (baxdrostat) achieving meaningful blood pressure reductions in resistant hypertension and an APOC3 antisense therapy (olezarsen) reducing acute pancreatitis in severe hypertriglyceridemia. Translational nephrology progressed via a microbiota-derived peptide (corisin) with antibody
Summary
Endocrinology in 2025-Q4 coalesced around actionable cardio-renal-metabolic therapeutics and mechanistic blueprints for disease modification. First-in-class clinical advances included an aldosterone synthase inhibitor (baxdrostat) achieving meaningful blood pressure reductions in resistant hypertension and an APOC3 antisense therapy (olezarsen) reducing acute pancreatitis in severe hypertriglyceridemia. Translational nephrology progressed via a microbiota-derived peptide (corisin) with antibody proof-of-concept and a nutrient–metabolism axis (BCAA–PKM2) that links podocyte apoptosis to diabetic kidney disease progression. β-cell preservation efforts were informed by human islet recovery transcriptomes and a TRAF6-governed mitophagy node, while pragmatic care was advanced by a randomized Bayesian decision-support system for MDI insulin titration. Cross-cutting biology featured exosomal CtBP2 as a geroscience signal and a structural map of the Adig–seipin lipid-droplet axis, broadening druggable targets across metabolism.
Selected Articles
1. Microbiota-derived corisin accelerates kidney fibrosis by promoting cellular aging.
Translational work identifies corisin as elevated in diabetic CKD and mechanistically linked to fibrosis via senescence, EMT, and apoptosis; an anti-corisin monoclonal antibody reduced nephropathy severity in diabetic mice.
Impact: Bridges human biomarker association with in vivo interventional proof, nominating a first-in-class anti-fibrotic target in DKD.
Clinical Implications: Positions serum corisin for DKD risk stratification and supports early-phase development of anti-corisin biologics pending safety evaluation.
Key Findings
- Serum corisin correlates with DKD stage and renal function decline.
- Anti-corisin mAb attenuates inflammation and fibrosis in diabetic mice.
- Corisin binds albumin and promotes senescence, EMT, and apoptosis in kidney cells.
2. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.
A phase 3, double-blind, multinational RCT (n=794) showed baxdrostat 1–2 mg reduced seated systolic BP by approximately 8.7–9.8 mmHg versus placebo at 12 weeks in uncontrolled/resistant hypertension, with modestly increased hyperkalemia.
Impact: Provides high-level evidence for a first-in-class aldosterone synthase inhibitor with clinically meaningful BP lowering in difficult-to-control hypertension.
Clinical Implications: Supports a new add-on for resistant hypertension, particularly for aldosterone-driven phenotypes, with routine potassium monitoring and need for longer-term outcomes.
Key Findings
- Placebo-corrected seated SBP reduction of −8.7 to −9.8 mmHg at 12 weeks (P<0.001).
- Hyperkalemia occurred infrequently but more often than with placebo.
- Consistent BP lowering on top of multidrug backgrounds including diuretics.
3. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.
Two double-blind RCTs (n=1,061) found monthly olezarsen lowered triglycerides by ~49–72 percentage points versus placebo at 6 months and reduced acute pancreatitis incidence (rate ratio 0.15), with dose-related hepatic effects at 80 mg.
Impact: First large randomized evidence that an APOC3 antisense agent both lowers triglycerides and reduces a hard clinical outcome (acute pancreatitis).
Clinical Implications: Provides a potent option for severe hypertriglyceridemia with outcome benefit; requires monitoring of liver enzymes, platelets, and hepatic fat.
Key Findings
- Placebo-adjusted triglyceride reductions of −49.2% to −72.2% at 6 months (P<0.001).
- Acute pancreatitis incidence substantially reduced (rate ratio 0.15).
- Higher-dose regimen associated with more enzyme elevations, thrombocytopenia, and hepatic fat increase.
4. Prevention of type 2 diabetes through prediabetes remission without weight loss.
Post hoc analyses of PLIS with replication in the US DPP show that achieving prediabetes remission—even without weight loss—reduces incident T2D, with signals for improved insulin sensitivity, enhanced β-cell GLP-1 responsiveness, and adipose redistribution.
Impact: Reframes prevention goals beyond weight loss by elevating glycaemic remission as a protective target with replicated mechanistic insights.
Clinical Implications: Supports explicit glycaemic remission targets in prevention programs and tracking of glycaemic metrics beyond weight, with interventions enhancing insulin sensitivity and β-cell responsiveness.
Key Findings
- Prediabetes remission without weight loss protects against incident T2D.
- Remission ties to improved insulin sensitivity and increased β-cell GLP-1 responsiveness.
- Findings reproduced in the US DPP cohort.
5. A Bayesian decision support system for automated insulin doses in adults with type 1 diabetes on multiple daily injections: a randomized controlled trial.
In adults with type 1 diabetes on MDI and CGM, a 12-week randomized trial showed a Bayesian decision support system delivering weekly basal and prandial dosing recommendations reduced HbA1c by 0.40% versus a non-adaptive bolus calculator without increasing severe hypoglycemia or DKA.
Impact: Delivers randomized, clinically meaningful HbA1c reduction via algorithmic titration in MDI users, expanding access where closed-loop systems are unavailable.
Clinical Implications: Supports deployment of validated decision-support tools integrated with CGM to optimize weekly dosing without increasing severe hypoglycemia risk.
Key Findings
- HbA1c reduction of 0.40% versus control over 12 weeks (p=0.025).
- No severe hypoglycemia or DKA events in either arm.
- Feasible weekly algorithm-driven basal and prandial dosing alongside CGM.
6. Functional recovery of islet β cells in human type 2 diabetes: Transcriptome signatures unveil therapeutic approaches.
Human islet transcriptomic signatures associated with β-cell functional recovery were defined across remission-inducing contexts, mapping targetable pathways and candidate biomarkers to prioritize disease-modifying interventions in T2D.
Impact: Provides a human-tissue molecular framework to identify and prioritize targets for β-cell recovery.
Clinical Implications: Enables biomarker-driven selection and early-phase testing of interventions aiming for sustained β-cell function and remission.
Key Findings
- Defined recovery-linked transcriptomic signatures in human islets after remission-inducing interventions.
- Mapped therapeutic pathways and candidate biomarkers to track β-cell recovery.
- Resource to prioritize disease-modifying strategies in T2D.
7. Branched-chain amino acids contribute to diabetic kidney disease progression via PKM2-mediated podocyte metabolic reprogramming and apoptosis.
Mechanistic work connects podocyte BCAA catabolic defects to DKD initiation through PKM2 depolymerization, metabolic diversion, and DDIT3–Chac1/Trib3-driven apoptosis, nominating restoration of BCAA catabolism and PKM2 activation as therapeutic strategies.
Impact: Defines an actionable metabolic axis (BCAA–PKM2) linking nutrient excess to podocyte apoptosis and DKD progression.
Clinical Implications: Discourages high-dose BCAA supplementation in diabetes and prioritizes development of PKM2 activators or BCAA catabolism–restoring approaches.
Key Findings
- Human DKD podocytes and db/db mice show BCAA catabolic defects.
- Podocyte PP2Cm knockout or BCAA excess induces DKD phenotypes.
- BCAAs trigger PKM2 depolymerization and nuclear PKM2–DDIT3 signaling to activate apoptosis programs.
8. TRAF6 integrates innate immune signals to regulate glucose homeostasis via Parkin-dependent and Parkin-independent mitophagy.
Using mouse genetics and human islets, TRAF6 was shown to be critical under metabolic stress for insulin secretion, mitochondrial respiration, and mitophagy; it coordinates Parkin-dependent mitophagy, and Parkin deletion can rescue TRAF6 loss via receptor-mediated mitophagy.
Impact: Reveals a cross-regulatory node linking innate immune signaling to mitophagy that preserves β-cell function under diabetogenic stress.
Clinical Implications: Nomination of mitophagy pathway components for pharmacologic modulation to preserve β-cell function; mitophagy biomarkers may aid stratification.
Key Findings
- TRAF6 is essential for insulin secretion, mitochondrial respiration, and mitophagy in stressed islets.
- TRAF6 coordinates Parkin-dependent mitophagy; Parkin deletion rescues TRAF6 loss via receptor-mediated mitophagy.
- Defines a cross-regulatory node for Parkin-dependent and -independent mitophagy in β cells.
9. The secreted metabolite sensor CtBP2 links metabolism to healthy lifespan.
CtBP2 is secreted in exosomes in response to reductive metabolism; exosomal CtBP2 extends lifespan and reduces frailty in aged mice via CYB5R3 and AMPK activation, and human serum CtBP2 declines with age and inversely associates with cardiovascular disease.
Impact: Identifies a secreted, exosome-mediated metabolic sensor with causal effects on lifespan in mice and correlations in humans, expanding biomarker and interventional avenues in aging and metabolism.
Clinical Implications: Merits prospective validation of serum/exosomal CtBP2 as a biomarker of biological aging and cardiometabolic risk; exosome- or CtBP2-targeted strategies may be explored after safety evaluation.
Key Findings
- Exosomal CtBP2 extends lifespan and reduces frailty in aged mice.
- CtBP2 activates CYB5R3 and AMPK signaling.
- Human serum CtBP2 declines with age and inversely associates with cardiovascular disease.
10. Adipogenin promotes the development of lipid droplets by binding a dodecameric seipin complex.
Cryo-EM and in vivo models show adipogenin selectively binds dodecameric seipin, bridging and stabilizing subunits to promote lipid droplet biogenesis; mouse genetics link Adig to adiposity and brown-fat triglyceride storage.
Impact: Provides a mechanistic, high-resolution structural basis for lipid droplet formation with in vivo validation, opening a druggable axis for lipid-storage disorders and obesity biology.
Clinical Implications: Suggests Adig–seipin modulation as a translational target for lipodystrophy or obesity therapies, pending human validation and safety profiling.
Key Findings
- Mammalian seipin forms undecamers and dodecamers; Adig selectively binds dodecamers.
- Adig bridges and stabilizes adjacent seipin subunits to promote lipid droplet development.
- Adig modulation alters adiposity and brown-fat triglyceride storage in mice.